top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Peter A, MD

16 Juni 2021, 19:15:44

Erythromycin na ujauzito

Erythromycin na ujauzito

Erythromycin ni dawa ya antibiotiki katika kundi la macrolide, dawa zingine katika kundi hili ni azithromycin, clarithromycin, dirithromcin na troleadomycin.


Ripoti nyingi ikiwa pamoja na tafiti kwa wanyama hazijapata ushahidi wa sumu kwenye ukuaji wa kichanga kwa kutumia dawa ya erythromycin. Hata hivyo ripoti moja imegundua kuwepo na uhusiano wa dawa Erythromycin na madhaifu ya kimaumbile ya moyo kwa vichanga wanaozaliwa licha ya mtafiti kutoweza kusema kama mahusiano hayo ni ya moja kwa moja au ni kutokana na sababu zingine walizokuwa nazo wajawazito hao.


Pia hakuna ushahidi wa kutosha kwamba matumizi ya erythromycin kipindi cha tatu cha ujauzito husababisha kuziba koki ya pailoriki kwa kichanga kama ilivyoonekana kwa baadhi ya tafiti


Kwa sababu hakuna tafiti nyingi zinazoonyesha hatari ya dawa hii kwenye ujauzito, erythromycin inaweza kutumika kwenye ujauzito kama kuna ulazima.


Ushauri dhidi ya matumizi ya Erythromycin kwa mjamzito


Inapatana na ujauzito isipokuwa chumvi yake estolate ambayo ina madhara kwenye ujauzito


Inapatana na ujauzito isipokuwa chumvi yake estolate in manisha nini?

Uzoefu wa matumizi kwa binadamu kuhusu Erythromycin au dawa zingine zilizo kundi moja au zenye kufanya kazi kwa utaratibu unaofanana, zinatosha kuonyesha kuwa, madhara kwa kichanga tumboni ni madogo sana au hakuna kabisa. Tafiti za uzazi kwa wanyama hazina uhalisia kwa binadamu.


Matumizi ya chumvi ya estolate ya erythromycin katika ujauzito huwa ni sumu kwenye ujauzito katika kipindi cha pili cha ujauzito, sumu hiyo huisha kama dawa ikiacha kutumika.


Ushauri wa matumizi ya Erythromycin kwa mama anayenyonyesha


Inapatana na unyonyeshaji


Inapatana na unyonyeshaji ina maanisha nini?

Kiasi kidogo cha Erythromycin kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Erythromycin haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 18:48:16

​

  1. Product information. Ery-Tab. Abbott Laboratories, 2000.

  2. Heilman FR, Herrell WE, Wellman WE, Geraci JE. Some laboratory and clinical observations on a new antibiotic, erythromycin (Ilotycin). Proc Staff Meet Mayo Clin. 1952;27:285–304.

  3. Kiefer L, Rubin A, McCoy JB, Foltz EL. The placental transfer of erythromycin. Am J Obstet Gynecol. 1955;69:174–7.

  4. Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med. 1973;288:1219–20.

  5. Fenton LJ, Light LJ. Congenital syphilis after maternal treatment with erythromycin. Obstet Gynecol. 1976;47:492–4.

  6. Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther. 1976;19:68–77.

  7. McCormack WM, George H, Donner A, Kodgis LF, Albert S, Lowe EW, Kass EH. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother. 1977;12:630–5.

  8. Jaffe P, Liberman MM, McFadyen I, Valman HB. Incidence of congenital limb-reduction deformities. Lancet. 1975;1:526–7.

  9. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group; 1977.

  10. Gallagher JC, Ismail MA, Aladjem S. Reduced urinary estriol levels with erythromycin therapy. Obstet Gynecol. 1980;56:381–2.

  11. Merenstein GB, Todd WA, Brown G, Yost CC, Luzier T. Group B B-hemolytic streptococcus: randomized controlled treatment study at term. Obstet Gynecol. 1980;55:315–8.

  12. Easmon CSF, Hastings MJG, Deeley J, Bloxham B, Rivers RPA, Marwood R. The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci. Br J Obstet Gynaecol. 1983;90:633–5.

  13. Quinn PA, Shewchuk AB, Shuber J, Lie KI, Ryan E, Chipman ML, Nocilla DM. Efficacy of antibiotic therapy in preventing spontaneous pregnancy loss among couples colonized with genital mycoplasmas. Am J Obstet Gynecol. 1983;145:239–44.

  14. Kass EH, McCormack WM. Genital mycoplasma infection and perinatal morbidity. N Engl J Med. 1984;311:258.

  15. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol. 1999;13:531–6.

  16. Kenyon SL, Taylor DJ, Tarnow-Mordi W, for the ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet. 2001;357:979–88.

  17. Kallen BAJ, Olausson PO. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255–61.

  18. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139:380–4.

  19. Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol. 2002;186:288–90.

  20. Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol. 2002;100:101–6.

  21. Sørensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schønheyder HC. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis. 2003;35:104–6.

  22. FitzSimmons J, Callahan C, Shanahan B, Jungkind D. Chlamydial infections in pregnancy. J Reprod Med. 1986;31:19–22.

  23. Black-Payne C, Ahrabi MM, Bocchini JA Jr, Ridenour CR, Brouillette RM. Treatment of Chlamydia trachomatis identified with chlamydiazyme during pregnancy: impact on perinatal complications and infants. J Reprod Med. 1990;35:362–7.

  24. Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following successful treatment of chlamydial infection. JAMA. 1990;263:3160–3.

  25. Magat AH, Alger LS, Nagey DA, Hatch V, Lovchik JC. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy. Obstet Gynecol. 1993;81:745–9.

  26. Alary M, Joly J-M, Mondor M, Boucher M, Fortier A, Pinault J-J, Paris G, Carrier S, Chamberland H, Bernatchez H, Paradis J-F. Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydia infection in pregnancy. Lancet. 1994;344:1461–5.

  27. Turrentin MA, Newton ER. Amoxicillin or erythromycin for the treatment of antenatal chlamydial infection: a meta-analysis. Obstet Gynecol. 1995;86:1021–5.

  28. Knowles JA. Drugs in milk. Pediatr Currents. 1972;21:28–32.

  29. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168:1393–9.

  30. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. Breastfeed Med. 2009;4:157–200.

  31. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.

bottom of page